| Population 2012
|
97 million
|
| |
| | |
| Estimates of TB burden * 2012
|
Number (thousands)
|
Rate
(per 100 000 population)
|
| Mortality (excludes HIV+TB)
|
23
|
(22–25)
|
24
|
(22–26)
|
| Mortality (HIV+TB only)
|
0.11
|
(0.09–0.13)
|
0.11
|
(0.09–0.14)
|
| Prevalence (includes HIV+TB)
|
450
|
(390–500)
|
461
|
(405–520)
|
| Incidence (includes HIV+TB)
|
260
|
(210–310)
|
265
|
(219–316)
|
| Incidence (HIV+TB only)
|
0.46
|
(0.38–0.55)
|
0.48
|
(0.39–0.57)
|
| Case detection, all forms (%)
|
84
|
(71–100)
|
|
|
| |
| | |
| TB case notifications 2012
|
|
|
|
|
| New cases
|
|
(%)
|
Retreatment cases
|
(%)
|
| Smear-positive
|
94 006
|
(44)
|
Relapse
|
4 084
|
(23)
|
| Smear-negative
|
115 263
|
(54)
|
Treatment after failure
|
591
|
(3)
|
| Smear-unknown / not done
|
0
|
(0)
|
Treatment after default
|
1 246
|
(7)
|
| Extrapulmonary
|
3 274
|
(2)
|
Other
|
11 698
|
(66)
|
| Other
|
0
|
(0)
|
|
|
|
| Total new
|
212 543
|
|
Total retreatment
|
17 619
|
|
|
|
|
|
|
|
|
| Other (history unknown)
|
0
|
|
|
|
|
| Total new and relapse
|
216 627
|
|
Total cases notified
|
230 162
|
|
| |
| | |
| New cases
|
Smear-positive
|
Smear-negative/ unknown/
not done
|
Extrapulmonary
|
| M:F ratio
|
2.3
|
1.6
|
1.2
|
| Age < 15
|
1 049
|
|
|
| | |
| | |
| Laboratories
|
2012
|
| Smear (per 100 000 population)
|
2.7
|
| Culture (per 5 million population)
|
0.7
|
| Drug susceptibility testing (per 5 million population)
|
0.2
|
| Is second-line drug susceptibility testing available?
|
Yes, in country
|
| |
| | |
| Treatment success rate 2011 (%)
|
|
|
|
|
| New smear-positive and/or culture-positive
|
90
|
|
Is rifampicin used
throughout treatment for
new patients?
|
Yes
|
| New smear-negative/extrapulmonary
|
85
|
|
| Retreatment
|
65
|
|
| |
| | |
| TB/HIV 2012
|
Number
|
(%)
|
| TB patients with known HIV status
|
2 040
|
(<1)
|
| HIV-positive TB patients
|
4
|
(<1)
|
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
|
|
| HIV-positive TB patients on antiretroviral therapy (ART)
|
|
|
| HIV-positive people screened for TB
|
|
|
| HIV-positive people provided with IPT
|
|
|
| | |
| | |
| Estimates of MDR-TB burden 2012*
|
|
New
|
|
Retreatment
|
| % of TB cases with MDR-TB
|
4
|
(2.9–5.5)
|
21
|
(14–29)
|
MDR-TB cases among notified pulmonary
TB cases
|
8 500
|
(6 000–11 000)
|
3 700
|
(2 500–5 100)
|
| |
| | |
| Reported cases of MDR-TB 2012
|
New
|
Retreatment
|
Total
|
| Cases tested for MDR-TB
|
35 (<1%)
|
2 038 (12%)
|
2 107
|
| Laboratory-confirmed MDR-TB cases
|
11
|
653
|
679
|
| Patients started on MDR-TB treatment
|
|
|
1 918
|
| |
| | |
| Financing TB control
|
2013
|
| National TB programme budget (US$ millions)
|
149
|
| % Funded domestically
|
16%
|
| % Funded internationally
|
15%
|
| % Unfunded
|
69%
|
| |
| | |